[go: up one dir, main page]

DE69027187D1 - Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen - Google Patents

Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen

Info

Publication number
DE69027187D1
DE69027187D1 DE69027187T DE69027187T DE69027187D1 DE 69027187 D1 DE69027187 D1 DE 69027187D1 DE 69027187 T DE69027187 T DE 69027187T DE 69027187 T DE69027187 T DE 69027187T DE 69027187 D1 DE69027187 D1 DE 69027187D1
Authority
DE
Germany
Prior art keywords
plasma
virus
polluted
pharmaceutical compositions
blood product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69027187T
Other languages
English (en)
Other versions
DE69027187T2 (de
Inventor
Michael Hrinda
Alisa Rose D
George Tarr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rorer International Overseas Inc
Original Assignee
Rorer International Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer International Overseas Inc filed Critical Rorer International Overseas Inc
Application granted granted Critical
Publication of DE69027187D1 publication Critical patent/DE69027187D1/de
Publication of DE69027187T2 publication Critical patent/DE69027187T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69027187T 1989-06-15 1990-06-13 Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen Expired - Lifetime DE69027187T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36685589A 1989-06-15 1989-06-15
PCT/US1990/003355 WO1990015613A1 (en) 1989-06-15 1990-06-13 Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69027187D1 true DE69027187D1 (de) 1996-07-04
DE69027187T2 DE69027187T2 (de) 1996-10-31

Family

ID=23444851

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69027187T Expired - Lifetime DE69027187T2 (de) 1989-06-15 1990-06-13 Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen

Country Status (9)

Country Link
US (1) US5300433A (de)
EP (1) EP0431129B1 (de)
JP (1) JP3297433B2 (de)
AT (1) ATE138575T1 (de)
CA (1) CA2034489C (de)
DE (1) DE69027187T2 (de)
DK (1) DK0431129T3 (de)
ES (1) ES2087156T3 (de)
WO (1) WO1990015613A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
JP3133338B2 (ja) * 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
WO1996032130A1 (en) * 1995-04-10 1996-10-17 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US7038016B2 (en) * 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
WO2003072032A2 (en) * 2002-02-22 2003-09-04 Intracel Resources Llc Sterile immunogenic non-tumorigenic tumor cell compositions and methods
CA2498518A1 (en) * 2002-09-13 2004-03-25 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
CN1933850B (zh) * 2004-03-22 2011-01-12 索尔瓦药物有限公司 含表面活性剂的、含脂肪酶产品尤其是胰酶的口服药物组合物
WO2006023774A2 (en) * 2004-08-20 2006-03-02 Imquest Biosciences, Inc. Plasma or serum fraction for treatment and prevention of viral infections and related conditions
HUE034739T2 (en) 2005-07-29 2018-02-28 Abbott Laboratories Gmbh Reduced viral pancreatin
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
WO2012069474A2 (en) * 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
ATE111490T1 (de) * 1983-10-28 1994-09-15 New England Medical Center Inc Verfahren zur isolierung eines proteins aus einer dieses protein enthaltenden mischung unter verwendung eines konformationsspezifischen antikörpers.
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (de) * 1985-04-26 1988-03-10 Immuno Ag Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
DD264137A1 (de) * 1987-09-22 1989-01-25 Univ Leipzig Mittel zur bekaempfung von viren in kulturpflanzen

Also Published As

Publication number Publication date
DE69027187T2 (de) 1996-10-31
DK0431129T3 (da) 1996-06-17
ATE138575T1 (de) 1996-06-15
EP0431129A1 (de) 1991-06-12
EP0431129A4 (en) 1992-03-11
CA2034489C (en) 1996-07-16
ES2087156T3 (es) 1996-07-16
EP0431129B1 (de) 1996-05-29
JPH04501429A (ja) 1992-03-12
US5300433A (en) 1994-04-05
WO1990015613A1 (en) 1990-12-27
JP3297433B2 (ja) 2002-07-02
CA2034489A1 (en) 1990-12-16

Similar Documents

Publication Publication Date Title
DE69027187D1 (de) Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
ATE54828T1 (de) Behandlung von auf einer festen phase adsorbierten biologischen und pharmazeutischen produkten mit viren und pyrogenen inaktivierenden agenzien.
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
ATE194921T1 (de) Verfahren zur inaktivierung von viren
JPH06102627B2 (ja) 脂質含有ウイルスを含まない蛋白質含有組成物及びその製造方法
ATE286407T1 (de) Verfahren zur inaktivierung von pathogenen mittels breitspektrum-pulslicht
KR950010898A (ko) 재조합 사람 혈청 알부민 약제학적 제제의 멸균법
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
DE69230643D1 (de) Methode zur behandlung von viralen infektionen
ATE44877T1 (de) Verfahren zur pasteurisierung von humanplasma.
ATE42899T1 (de) Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix, und x.
DE3786838D1 (de) Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern.
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
ATE194648T1 (de) Verfahren zur inaktivierung von viren in präparationen von proteinen
DE3750886D1 (de) Verwendung eines immunglobulinhaltigen Präparates zur Prophylaxe und Therapie von AIDS beim Menschen.
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
FI93696B (fi) Kymotrypsiinin käyttö prekallikreiini-aktivaattorin tehottamiseksi tekemiseksi
Shanbrom Choice of replacement therapy for hemophilia—reply to a rebuttal
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC